DNA X, Inc. (SONM)
Official siteFINANCIAL SERVICES • COMMUNICATION EQUIPMENT • NASDAQ
Market Cap: $3.23M
Last updated: Nov 17, 2026 at 11:02 AM ET
DNA X, Inc. (SONM) Financials: Revenue, Profit and Cash Flow
DNA X reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.66M, operating cash flow was -$23.53M and free cash flow was -$23.53M. The quarter ended Jun 30, 2026 had revenue of -$11.00K and net income of -$1.25M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $5.41M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $93.63M | +34.1% | 20.6% | 0.5% | -0.1% |
| Dec 2022 | $69.83M | +28.0% | 16.6% | -20.5% | -20.2% |
| Dec 2021 | $54.57M | -14.7% | 11.8% | -69.6% | -70.8% |
| Dec 2020 | $63.99M | -45.0% | 23.8% | -45.7% | -46.8% |
| Dec 2019 | $116.25M | -14.3% | 29.7% | -19.3% | -22.2% |
| Dec 2018 | $135.66M | +129.8% | 35.4% | 4.0% | 0.9% |
| Dec 2017 | $59.03M | N/A | 34.4% | -11.5% | -14.4% |
| Dec 2000 | $2.85M | N/A | 39.6% | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2000 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $93.63M | $69.83M | $54.57M | $63.99M | $116.25M | $135.66M | $59.03M | $2.85M |
| Cost of revenue | $0 | $0 | $74.31M | $58.20M | $48.16M | $48.78M | $81.74M | $87.58M | $38.72M | $1.72M |
| Gross profit | $0 | $0 | $19.32M | $11.62M | $6.41M | $15.21M | $34.51M | $48.09M | $20.31M | $1.13M |
| Research and development | $0 | $0 | $1.77M | $7.97M | $17.70M | $16.22M | $26.06M | $23.25M | $13.01M | $0 |
| Operating income | -$5.41M | -$3.10M | $513.00K | -$14.29M | -$38.00M | -$29.26M | -$22.38M | $5.39M | -$6.77M | N/A |
| Net income | -$20.66M | -$33.65M | -$90.00K | -$14.09M | -$38.63M | -$29.93M | -$25.83M | $1.28M | -$8.52M | N/A |
| EBITDA | -$2.01M | $703.00K | $2.50M | -$11.43M | -$36.33M | -$26.64M | -$19.31M | $5.71M | -$6.25M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -$11.00K | $0 | -$44.13M | $16.21M | $0 | $0 | -$43.31M | $15.02M | $11.52M | $16.78M | $13.43M | $27.57M |
| Gross profit | -$11.00K | $0 | -$11.02M | $1.82M | $0 | $0 | -$10.10M | $4.23M | $2.97M | $2.90M | $5.12M | $5.60M |
| Operating income | -$1.28M | -$3.62M | $4.66M | -$3.98M | -$1.47M | -$870.00K | $8.44M | -$2.38M | -$6.47M | -$2.69M | -$1.25M | $688.00K |
| Net income | -$1.25M | $6.34M | -$8.89M | -$4.75M | -$7.47M | $458.00K | -$21.61M | -$2.51M | -$6.62M | -$2.91M | -$1.35M | $527.00K |
Balance Sheet
As of Dec 2025, short-term debt of $5.07M exceeded cash and equivalents by $3.76M. Shareholder equity was negative, at -$7.96M, as total liabilities of $50.63M exceeded total assets of $43.90M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2000 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $43.90M | $39.74M | $56.04M | $53.69M | $41.09M | $50.31M | $55.46M | $67.34M | $30.25M | $1.05M |
| Current assets | $28.91M | $32.16M | $43.79M | $43.63M | $35.69M | $45.57M | $47.34M | $63.87M | $27.37M | N/A |
| Cash and equivalents | $1.30M | $5.34M | $9.40M | $13.21M | $11.23M | $22.14M | $11.30M | $13.05M | $1.58M | $103.00K |
| Total liabilities | $50.63M | $45.44M | $33.67M | $33.64M | $22.46M | $21.90M | $29.93M | $62.22M | $39.76M | $4.05M |
| Short-term debt | $5.07M | $0 | $55.00K | $147.00K | $148.00K | $177.00K | $9.82M | $301.00K | $3.13M | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | $66.00K | $185.00K | $362.00K | $13.21M | $7.55M | $351.00K |
| Shareholder equity | -$7.96M | -$5.70M | $22.37M | $20.05M | $18.63M | $28.41M | $25.52M | $5.13M | -$9.51M | -$2.99M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.52M | $4.84M | $43.90M | $40.22M | $36.08M | $35.96M | $39.74M | $49.15M | $45.87M | $42.38M | $56.04M | $58.61M |
| Total liabilities | $5.75M | $4.92M | $50.63M | $40.92M | $37.41M | $37.04M | $45.44M | $33.80M | $28.40M | $22.55M | $33.67M | $35.50M |
| Cash and equivalents | $900.00K | $1.20M | $1.30M | $2.14M | $2.01M | $2.12M | $5.34M | $9.06M | $9.60M | $9.25M | $9.40M | $9.80M |
| Shareholder equity | -$1.23M | -$983.00K | -$6.73M | -$701.00K | -$1.33M | -$1.08M | -$5.70M | $15.35M | $17.47M | $19.84M | $22.37M | $23.11M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.53M | -$8.49M | -$4.05M | -$12.36M | -$38.48M | -$10.56M | -$33.52M | $3.86M | -$8.91M |
| Capital expenditures | $0 | $214.00K | $36.00K | $8.00K | $46.00K | $11.00K | $1.36M | $2.54M | $1.17M |
| Free cash flow | -$23.53M | -$8.70M | -$4.09M | -$12.37M | -$38.52M | -$10.57M | -$34.88M | $1.32M | -$10.08M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $6.00K | $1.90M | N/A | N/A |
| Investing cash flow | $0 | -$214.00K | -$36.00K | -$8.00K | -$46.00K | -$11.00K | -$1.36M | -$2.54M | -$999.00K |
| Financing cash flow | $19.49M | $4.65M | $272.00K | $14.35M | $27.61M | $21.41M | $33.13M | $10.15M | $4.42M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.00M | -$3.47M | -$2.00M | -$7.03M | -$4.88M | -$9.61M | -$4.51M | -$417.00K | -$3.39M | -$168.00K | -$351.00K | -$304.00K |
| Capital expenditures | N/A | $0 | $0 | $0 | $0 | $8.00K | $8.00K | $137.00K | $39.00K | $30.00K | $12.00K | $1.00K |
| Free cash flow | N/A | -$3.47M | -$2.00M | -$7.03M | -$4.88M | -$9.61M | -$4.52M | -$554.00K | -$3.43M | -$198.00K | -$363.00K | -$305.00K |
Frequently Asked Questions About SONM
What is DNA X's annual revenue?
DNA X reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is DNA X profitable?
No. DNA X reported net income of -$20.66M for the fiscal year ended Dec 31, 2025.
How much free cash flow does SONM generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.53M minus capital expenditures of $0 produced free cash flow of -$23.53M.
How much debt does DNA X have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.07M and cash and equivalents of $1.30M.
SONM pages: Overview, Earnings, Financials, Competitors